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Colorectal cancer is the third most common cancer among both men and women in the United States and the second leading
cause of cancer death. Endoscopic submucosal dissection (ESD) is an innovative advanced endoscopic therapy for superficial
gastrointestinalneoplasmswhichisrapidlybecomingstandardofcareparticularlyinAsia.ESDwasfirstdevelopedfortheresection
of early gastric cancers; yet ESD for colon tumors has gained increasing attention in recent years. The advantage of ESD over
conventional endoscopic resection lies in its potential to achieve en bloc resection regardless of tumor size, leading to more
precise histological evaluation and greater potential for cure. Selecting appropriate patients for this procedure involves identifying
colorectal cancers with nul risk of lymph node spread. For colorectal ESD to engraft in the United States, the prevalence of such
early stage lesions must be defined so that centers of excellence can be developed for high volume clinical practice to offer patients
the safest and most efficacious outcomes. This review discusses the endoscopic staging of colorectal neoplasms, indications for
colorectal ESD, and the epidemiology of early stage ESD-amenable colorectal cancer in America to better define an opportunity
for this important minimally invasive therapy.
1. Introduction: Endoscopic Submucosal
Dissection and Colorectal Neoplasia
Cancers of the colon and rectum are the third most common
cancersamongbothmenandwomenintheUnitedStatesand
thesecondleadingca useofcancerdea th[1].Endoscopicsub-
mucosal dissection (ESD) is an innovative advanced endo-
scopic approach to superficial gastrointestinal neoplasms,
which is becoming the standard treatment, particularly in
advanced Asian medical centers [2, 3]. ESD was first utilized
in the resection of early gastric neoplasms; yet ESD for colon
tumors has gained increasing attention in recent years [4–9].
TheadvantageofESDoverconventionalendoscopicmucosal
r e s e c t i o ni st h a ti th a st h ep o t e n t i a lf o rah i g hr a t eo fe n
bloc resection regardless of tumor size, leading to precise
histological evaluation of the specimen margins and a lower
recurrence rate at long-term followup [5, 10–12]. In one
of the largest follow-up studies to date evaluating ESD for
colorectalepithelialneoplasmsincludingbothadenomasand
carcinomas, the 5-year overall/disease-specific survival was
greaterthan95%[10].Inananalysisofseveralstudiestotaling
greater than 700 cases of ESD for colorectal cancer, local
recurrence rates averaged approximately 1% [7]. Finally, in
a recent large-scale multicenter study of long-term outcomes
afterendoscopicresectionforsubmucosalinvasivecolorectal
cancer, among the patients with low risk features treated
by endoscopic resection alone, the 5-year recurrence-free
survivalandrecurrencerateswere98%and0.8%,respectively
[13].
Many experts believe that ESD will someday largely
replace colectomy for node-negative colorectal epithelial
neoplasia. One recent study in Japan evaluated patients with
intramucosal or slightly submucosal invasive colorectal can-
cer treatedwith ESD comparedwithpatientswho underwent
laparoscopic-assistedcolectomyforT1colorectalcancersand
concludedthatESDwasassociatedwithalowercomplication
rate and had favorable en bloc and curative resection rates
for early cancers with nul risk of lymph node metastasis [2].2 Diagnostic and Therapeutic Endoscopy
In an editorial from Endoscopy regarding this study, the
author stated: “it is a shame that the vast majority of patients
worldwide who have early cancers of the colon and rectum,
c o n fi n e dt ot h em u c o s a ,a r es u b j e c t e dt ol a p a r o s c o p i co r
open colon resections. This is wasteful of healthcare financial
resources and really is not optimal care for the patient.
There should be an international drive to get surgeons and
gastroenterologists up to speed on ESD, so that all patients
have access to the “best” treatment for these tumors [14].”
Barriers to the adoption of this technique in the United
States include greater technical difficulty with a substantial
learning curve and longer procedure times, a lack of gastric
cancer cases where ESD is easiest and safest to learn, risk
of complications such as bleeding and perforation as well
as the notable absence of reimbursement guidelines [15].
Selecting appropriate patients for this procedure involves
i d e n t i f y i n gc o l o r e c t a lc a n c e r sw i t hn u lr i s ko fl y m p hn o d e
s p r e a d .Th u s ,f o rc o l o r e c t a lE S Dt ot a k eh o l di nt h eU n i t e d
States, the prevalence of such early stage tumors needs to be
characterized so that high volume centers of excellence can
be developed to offer patients the safest and most efficacious
outcomes.
2. Selecting the Appropriate Lesion for ESD:
Endoscopic and Pathologic Assessment of
Colorectal Neoplasms
Determining which colorectal neoplastic lesions are amena-
b l et oe n d o s c o p i cr e s e c t i o ni sav a s tt o p i cw i t hm u c hp u b -
l i s h e dw o r ko nt h es u b j e c t .Th eH a g g i t t[ 16], Paris [17],
Vienna [18], and Kudo classification [19] systems are various
validatedtoolsforevaluatingandpredictingtheriskofmalig-
nancy and invasiveness of various epithelial lesions based
on the gross endoscopic appearance, chromoendoscopy,
and magnifying endoscopy. Notably, endoscopic ultrasound
( E U S )c a na l s ob eu s e dt oi n c r e a s et h ep r e d i c t i v ev a l u eo f
these classification systems.
Large studies have assessed the prognostic value of these
endoscopicstagingcategoriesinpredictingtheriskofsubmu-
c o s a li n v a s i o na sw e l la sr i s ko fl y m p hn o d em e t a s t a s i s[ 17].
Of note, the mucosa contains three layers from superficial to
deep: (1) epithelium with basement membrane, (2) lamina
propria, and (3) muscularis mucosae. Thus, the depth of
lesion penetration into the submucosal layer is measured
as the distance of invasion beyond the muscularis mucosa.
The risk of submucosal invasion and subsequent lymph
node spread is a central issue in the understanding of early
colorectalneoplasiaanditssubsequentmanagement.Lesions
with increased risk of nodal metastasis by current standards
require surgical staging which involves lymph node dissec-
tionandharvestforpathologicevaluation.Kudoetal.showed
in a large series of colorectal neoplasia that depressed-type
lesions of 6–10mm diameter showed submucosal invasion
in approximately 24%, as compared with 1.3% in protruding
lesions and 0.5% in flat or slightly elevated lesions, and these
statisticsincreasedwiththesizeofthelesion[19].Thus,while
fora type 0-I lesion, diameter is a reliable predictivecriterion
of the risk of submucosal invasion, with type 0-II lesions,
the morphologic subtypes have greater importance with the
depressed 0-IIc lesions having the greater risk [17]. In these
lesions,EUSwithhighfrequencyprobesat20MHzmayhave
an important role. Endoscopy tends to understage superfi-
cial lesions, while EUS tends to overstage them, and thus
combining these methods is highly predictive of submucosal
involvement [20]. Finally, regarding the prevalence of these
various lesion subtypes, in a large series of 9533 superficial
lesionsfromamajorJapanesecenter,57%were0-I,39%were
0-IIa,b, and only 4% were 0-IIc [21].
Classification of submucosal invasion is based on the
divisionofthesubmucosa(sm)intothreelayersofequivalent
thickness, from sm1 to sm3, superficial to deep. Sm1 lesions
are further subdivided into three categories (a, b, and c)
with regard to the degree of horizontal involvement of the
upper submucosal layer. While sm1a + b lesions have a very
low risk for metastasis, the malignant potential increases
with the depth of submucosal invasion. In addition to the
depth of invasion, involvement of the submucosal vessels
also portends increased risk of lymph node spread [19].
The risk of nodal metastases has been shown to be high
when the invasion reached sm3 near the muscularis propria.
On endoscopic mucosal resection (EMR) specimens, the
risk of nodal metastasis is nil or small when invasion into
the submucosa is less than 1000 micrometers below the
muscularis mucosae which corresponds to the sm1 layer [17].
Risks of nodal metastasis by sm layer have been reported
as sm1 = <1%, sm2 = 6%, and sm3 = 14% in a study of
over 300 “type 0” (superficial polypoid, flat/depressed, or
excavated)tumors[17].Onestudyof117submucosalinvasive
CRCs suggested that when submucosal invasion was less
than 850 micrometers in depth and 2500 micrometers in
width, there may be no risk of micrometastasis and that
EMRalonehascompletecurativepotentialinsuchcases[22].
Additionally, a significant study contributing to the Japanese
Society for Cancer of the Colon and Rectum’s 2012 guidelines
regarding T1-sm1 lesions was derived from a large cohort of
865 patients which found that for nonpedunculated submu-
cosal invasive colorectal carcinomas, the rate of lymph node
metastasiswas0%ifthesubmucosaldepthwaslessthan1000
micrometers[23,24].Thus,inlesionsresectedendoscopically
with subsequent pathologic evaluation revealing invasion
below the sm1 layer or in lesions demonstrating lymphatic
invasion, tumor budding, vascular involvement, or poorly
differentiated components, additional surgical resection for
lymphnodestagingwouldlikelyberecommendedwhichwas
also corroborated in a recent meta-analysis [25, 26].
Lastly, the tool of magnifying endoscopy in providing
an empirical description of the surface pattern of neoplastic
lesions can be highly predictive of invasive phenotypes of
various lesions which can significantly guide management
decisions. Such “pit patterns” have been carefully delineated
byKudoetal.[19].Thenoninvasivepitpatternissuggestiveof
intramucosalneoplasiaorsubmucosalinvasionlessthan1000
microns which is an appropriate indication for endoscopic
treatment. In a large series, histology confirmed this in 98%
of 2951 lesions with a noninvasive pattern. The invasive pit
pattern, characterized by irregular and distorted epithelial
crests, suggests that submucosal invasion is more than 1000Diagnostic and Therapeutic Endoscopy 3
microns. Histology confirmed deep submucosal invasion in
86% of 156 lesions with an invasive pattern [17]. Finally, a
recent study importantly assessed the ability of the narrow-
band imaging international colorectal endoscopic (NICE)
classificationtoruleoutdeepsubmucosalcarcinomainvasion
with a negative predictive value of 92% [27]. This simplified
endoscopic classification system holds promise to facilitate
the detection of submucosal involvement which is critical in
selecting appropriate patients for ESD.
3. Indications for Colorectal ESD:
Consensus Guidelines
The specific indications for colorectal ESD as recommended
by the Colorectal ESD Standardization Implementation
Working Group include [8, 28, 29]l a r g e - s i z e d( >20mm in
diameter)lesionsinwhichenblocresectionusingsnareEMR
is difficult including nongranular types of lateral spreading
tumor (particularly those of the pseudodepressed type),
lesions showing VI type pit pattern, carcinoma with sub-
mucosal infiltration less than 1000 microns, large depressed-
type lesions, and large elevated lesions suspected to be
carcinoma. Additional indications for ESD include mucosal
lesions with fibrosis related to biopsy, sporadic tumors in
chronic inflammation such as in ulcerative colitis, and local
residual carcinoma after endoscopic resection that fulfills
other aforementioned criteria. An additional indication for
ESD often cited includes an adenoma showing a nonlift-
ing sign. As mentioned previously, this evaluation is often
determined by endoscopic features, using chromoendoscopy
and occasionally magnifying endoscopy or EUS. EUS is used
for the unique cases of scarring lesions or when magnify-
ing endoscopy raises the suspicion of massive submucosal
invasion. Of note, biopsy is often not needed with adequate
chromoendoscopic exam, and, additionally, biopsy can lead
t os u b m u c o s a lfi b r o s i sw h i c hc a nl e a dt oi n c r e a s e dd i ffi c u l t y
a n dr i s ki ns u b s e q u e n te n d o s c o p i cr e s e c t i o n[ 7].
4. Colorectal TNM Classification: A Critical
Framework to Guide Therapy
Another important method for determining the prognosis
andmanagementofcolorectalneoplasmsistheTNMstaging
system as designated by the American Joint Committee on
Cancer (AJCC) [30]. According to the TNM classification
for malignant staging, the depth of tumor invasion in the
bowel wall corresponds to the T of the classification. Tm
(mucosa) and T (in situ) refer to intraepithelial tumors with
no invasion of the submucosa. These lesions only involve
the mucosa and thus have not grown beyond the muscularis
mucosa.Aspreviouslymentioned,themucosacontainsthree
layers from superficial to deep: (1) epithelium with basement
membrane, (2) lamina propria, and (3) muscularis mucosae.
In T1 lesions, the cancer has grown through the muscularis
mucosa and extends into the submucosa. These lesions are
sometimes referred to as T1sm. With respect to prevalence
of T1 lesions, in a cohort of 7,543 patients who underwent
operative treatment for carcinoma of the colon and rectum
from 1979 to 1995 at the Mayo Clinic, the incidence of T1
lesions was 8.6 percent; however, the depth of submucosal
invasion of these T1 lesions was not apparent [31]. The risk
of lymph node metastasis in T1 carcinomas of the colon and
rectum ranges from 6 to 14 percent citing several studies;
however, these studies did not overtly perform subgroup
a n a l y se so ft h es m 1 ,s m 2 ,a n ds m 3s u b m u c o s a ll a y e r s[ 31–33].
As notably aforementioned, the risks of nodal metastasis in
sm1 (which characterizes lesions that invade less than 1000
micrometers below the muscularis mucosae) have been cited
aslessthan1%(1/147patients)[17].However,asconcludedin
arecentstudyonrectalcancer,onlytheabsenceofhigh-grade
tumors, invasion of the muscular layer of the intestinal wall,
a n dl y m p h a t i ca n dv a s c u l a ri n v a s i o np r e d i c t e dt h es u c c e s s




in situ or intramucosal carcinoma. Stage I represents T1-
T2, N0, and M0 cancers. In stage I, the cancer invades
t h es u b m u c o s aa n dt h u sh a sg r o w nt h r o u g ht h em u s c u l a r i s
mucosa (T1) or may have grown into the muscularis propria
(T2) but involves no lymph nodes. According to the stages
definedbytheAJCCfiftheditionsystem,5-yearstage-specific





invasive and in situ cancer subtypes diagnosed in residents
of the 12 SEER geographic areas which collectively cover
about 14% of the total US population. The SEER program
follows all previously diagnosed patients on an annual basis
tocalculateobservedandrelativesurvivalrates[36].Between
1988 and 2001, the SEER database reported 247,671 cases
of colorectal cancer. After all exclusions, 182,589 cases were
evaluated in the SEER statistics (male = 92,880, female =
8 9 , 7 0 9 ,w h i t e=1 5 0 , 5 2 2 ,b l a c k=1 6 , 8 3 0 ,a n do t h e r=1 5 , 3 2 7 ) .
A total of 11,041 carcinoma in situ cases were excluded
from the analysis. It is unclear why stages 0 and 1 are
included as one category and it is also ambiguous why there
were 11,041 carcinoma in situ (CIS) patients not included
in the published analysis; however, given that stage 0 is
often synonymous with CIS, there appear to be many CIS
cases that are ultimately included in the 182,589 patients.
Of the 182,589 cases, 26.3% were classified as stage 0/1.
Stage 0/I colorectal cancers were further subdivided into the
depth of penetration into the wall based on SEER extent
of disease (EOD) extension codes. While in situ lesions
were excluded from the published SEER analysis, the AJCC
considers invasion of the lamina propria to be equivalent
to in situ or noninvasive disease. Thus, while cancers which
meetthesecriteriaareconsideredtobemalignantneoplasms,
with respect to AJCC stage they are classified as stage 0.
Thus, by this AJCC staging report, stage 0 is limited only
to those patients whose tumor had extended to the lamina
propria. Given that all stage 0 and some stage 1 colorectal
cancers are theoretically amenable to endoscopic treatments
(ESD and potentially EMR), further analysis of this data4 Diagnostic and Therapeutic Endoscopy
could be valuable with respect to determining the prevalence
of endoscopically treatable colorectal cancer in the United
States. In turn, this information could assist in establishing
t h en e e df o rE S Dc e n t e r so fe x c e l l e n c ei nA m e r i c a .I ti s
important to note that large adenomatous polyps represent
another significant category of lesions where ESD may have
ar o leinr ed ucin gra t eso flocalr ecurr enceco m pa r edt oo ther
conventionalendoscopicresectiontechniques.ESDmayalso
provideanorgan-sparingalternativeforadenomatouspolyps
which have been traditionally removed by surgery. Lastly,
given the aging demographics in our country, the burden
of colorectal cancers will likely increase further inviting
development of minimally invasive methods such as ESD to
treat these malignancies.
5. Conclusions: A Novel Opportunity
in Minimally Invasive Colorectal
Cancer Therapy
ESD is an innovative advanced endoscopic approach to
superficial gastrointestinal neoplasms which is increasingly
becomingastandardtreatmentparticularlyinAsianmedical
centers and has the potential to revolutionize treatment
of early alimentary cancers in America as well. Colorectal
cancer represents an important potential niche for clinical
application of ESD in the United States given the prevalence
ofthesetumors.GiventhetechnicaldifficultyofESD,further
ex vivo and in vivo training programs must be developed
to better define the learning curve for safe and effective
colorectal ESD. Additionally, reimbursement guidelines will
need to be created which address the time-consuming nature
and expert training required for this minimally invasive pro-
cedure. Further, in an era of increasing fiscal responsibility,
it is important to note that recent evidence suggests that
utilizing ESD for treatment of colorectal cancer may also
reduce costs compared with conventional surgical therapies
[2].CarefulpatientselectionwillbecriticaltosuccessfulESD
in identifying patients’ tumors with nul risk of lymph node
metastasis, necessitating additional training for US endo-
scopists in chromoendoscopy and Kudo/Paris preoperative
tumor classifications. Finally, for colorectal ESD to engraft in
the United States, the prevalence of early colorectal cancers
( s t a g e0a n ds t a g e1 ,s m 1 )m u s tb ed e fi n e ds ot h a tc e n t e r so f
excellence can be developed for high volume clinical practice
to offer patients the safest and most efficacious outcomes.
However, an important question remains as to whether the
biology of colon cancer in Asia may differ with respect to
t h ep r e v a l e n c eo fl a t e r a ls p r e a d i n gc a n c e r s .F u r t h e rs t u d i e s
are needed to clarify the epidemiology of early stage ESD-
amenable colorectal cancer in America to better define a role
for this important organ-sparing alternative to surgery.
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